Register for IPO Updates
US IPO Stats
IPO Industry Breakdown
Largest Global IPOs
Largest US IPOs
IPO News Archive
New Ways to Invest in IPOs - IPO ETFs
Week ahead: Two biotechs and a tech company
Analyst IPO Market Commentary
In the last week of October, no companies filed for an IPO.
October was a difficult month for IPOs:
16 companies went public
, pricing an average of 22% below their midpoint. Despite the massive valuation cuts, the average IPO return was just 3.4%, while the return on the S&P 500 in the month was 8.3%. However, 30 companies did file for an IPO in October, possibly indicating a stronger end to the year.
The technology sector, which was largely absent in the third quarter, saw three companies,
CPI Card Group
), go public in October. The three deals priced an average 32% below the midpoint, but they have returned 11% since then. Biotech companies faced similar pricing pressure (25% below the midpoint) this month, but returns were worse, essentially flat. One tech company and two biotech companies hope to price their IPOs next week.
In it for the long-haul
With a technological advantage rooted in its proprietary version of Raman amplification,
) believes it has solved the operational challenges that formerly hurt Raman adoption and believes that its products offer service providers a cost-effective way to respond to bandwidth constraints. In August 2015, competitor Ciena (NYSE: CIEN) acquired Cyan for about $415 million (net of cash acquired), and Infinera (Nasdaq: INFN) acquired Transmode for $350 million. Xtera Communications is set to raise $55 million at a valuation of $183 million (roughly 23% higher than its August 2015 valuation of $104 million, based on a stock purchase agreement).
IPO on a blind date
Founder-led and Novartis-backed
) is developing gene therapies for rare retinal diseases that cause blindness. Lead candidate GS010 is designed to be a one-shot cure for Leber hereditary optical neuropathy and the company expects to begin pivotal Phase 3 trials in the 4Q15. However, no gene therapies have ever been approved in the US. The company hopes to raise $65 million by offering shares at $14, an 81% premium to its last private round. That price could come down, especially considering that eight out of the last nine biotechs have priced below their respective ranges.
), which listed on the OTCQB through a reverse merger, looks to raise $60 million next week in an uplisting to the Nasdaq. The company is located in Johnson & Johnson’s San Diego-based biotech incubator, Janssen Labs. It is developing protein inhibitors for solid tumors and blood cancers and has begun Phase 2 clinical trials for lead candidate tipifarnib.
Renaissance Capital's IPO
- Week of
$13.00 - $15.00
Developing gene therapies for rare retinal diseases.
La Jolla, CA
$16.00 - $16.00
Developing in-licensed protein inhibitors for solid tumors and blood cancers.
$9.00 - $11.00
Needham & Co.
Cowen & Company
BMO Capital Markets
Provides optical transport systems for long-haul terrestrial/submarine networks.
First Guaranty Bancshares
$21.00 - $21.00
Louisiana bank with 21 branches and $1.5 billion in assets.
IPO Pipeline Update: No new filers this week
Even with no initial filings this week, October’s 30 filings is tied with 2013 as the
most active October
in the last ten years. We note that companies that hoped to price their IPOs before Thanksgiving would have needed to file already.
), which has similar backers to recent IPO
), set terms this week but has not set a pricing date for its $86 million IPO. Several companies updated their filings in anticipation of their IPOs, including high-growth craft brewer
Ballast Point Brewing Company
), which is looking to raise $173 million. Jack Dorsey’s
) also disclosed financials for the 3Q15.
) also updated its filing, announcing various agreements and insider buyers for an IPO that we estimate could raise up to $200 million.
IPO Market Snapshot
154 IPOs have raised $28.1 billion in 2015, but only 38% are trading above their IPO price. The Renaissance IPO Indices are market cap weighted baskets of newly public companies. The Renaissance IPO Index is down 5% year-to-date, compared to +1% for the S&P 500. Renaissance Capital's
(NYSE: IPO) tracks the index, and
top ETF holdings
include Alibaba (
), Twitter (
) and Hilton Worldwide (
). The Renaissance International IPO Index is down 3% year-to-date, in line with the ACWX. Renaissance Capital’s International
(NYSE: IPOS) tracks the index, and
top ETF Holdings
include Recruit Holdings and Samsung C+T.
Keywords / Tickers:
Recently Priced IPOs
ETF Express Award:
ETFExpress awards are based on a 'peer review system' whereby readers - including institutional and high net worth investors as well as managers and other industry professionals at fund administrators, brokers, custodians and advisers - are invited to elect a 'best in class' in a series of categories via an online survey. In each category, the firms with the most votes at the end of the voting period are subject to a final review by ETFExpress's Senior Editorial team.
Past performance does not guarantee future results. The performance data quoted represents past performance and current returns may be lower or higher. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than the original cost. Investors should consider the investment objectives, risks, charges and expenses carefully before investing.
As stated in the Prospectus, the total annual operating expenses for the Fund was 3.48%. The Adviser has contractually agreed to keep net expenses from exceeding 2.50% of the Fund's average daily net assets for at least a year from the date of the Prospectus and for an indefinite period thereafter subject to annual re-approval of the agreement by the Board of Trustees.
An investor cannot invest directly in an index. Index returns do not represent Fund returns. The Index does not charge management fees or brokerage expenses, nor does the Index lend securities, and no revenues from securities lending were added to the performance shown.
Definitions: Net Asset Value (NAV) of the fund is calculated by dividing the total value of all the securities in its portfolio, less any liabilities, by the number of fund shares outstanding. Market Price is current value at which an asset or service can be bought or sold. Premium/Discount is provided to show the comparison of the daily net asset value (NAV) and the midpoint of the closing bid/ask for each of the funds.
Renaissance IPO Index® (IPOUSA)
is a stock market index based upon a portfolio of U.S.-listed newly public companies that includes securities prior to their inclusion in core U.S. equity portfolios.
Renaissance International IPO Index® (IPOXUS)
is a stock market index based upon a portfolio of newly public companies listed on non-U.S. exchanges.
The S&P 500® Index (SPX) is a stock market index which includes 500 U.S. listed companies and seeks to capture approximately 80% coverage of available U.S. market capitalization.
Risk Disclosure: Investments in the
Renaissance IPO ETF, symbol "IPO"
Renaissance International IPO ETF, symbol "IPOS"
(the "ETFs"), and the
Global IPO Fund, symbol "IPOSX"
(the "Mutual Fund") are subject to investment risk, including possible loss of the principal amounts invested. The ETFs and the Mutual Fund (the "Funds") invest in companies that have recently completed initial public offerings. These stocks are unseasoned equities lacking trading history, a track record of reporting to investors and widely available research coverage which many result in extreme price volatility. Due to a greater number of IPOs in certain segments, the Funds may also be subject to information technology and financial sector risk, small and mid-capitalization company risk, and, for the Renaissance International IPO ETF, emerging markets risk. The Funds may hold securities in the form of Depository Receipts, REITs, and Partnership Units which have greater risks than common shares. The strategies have high portfolio turnover and securities lending risks. The returns of the ETFs may not match the return of the respective indices. The ETFs are classified as non-diversified investment companies subject to concentration risk.
Prospectus: Investors should consider the investment objectives, risks, charges and expenses carefully before investing. For a prospectus and/or summary prospectus with this and other information, please visit
. Read the prospectus carefully before investing. Renaissance Capital Investments, Inc., distributor for the Mutual Fund. Foreside Fund Services, LLC, distributor for the ETFs, 1-866-486-6645.
Definitions: The Renaissance IPO Index® is a stock market index based upon a portfolio of U.S.-listed newly public companies that includes securities prior to their inclusion in core U.S. equity portfolios. The S&P 500® Index is a stock market index based on the market capitalizations of 500 large companies whose common stock is publicly traded on the NYSE or Nasdaq.
The information contained herein is proprietary and copyrighted. The media is welcome to use our information and ideas, provided that the following sourcing is included: Renaissance Capital - manager of IPO-focused ETFs.
The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO), the Renaissance International IPO ETF (symbol: IPOS), or the Global IPO Fund (symbol: IPOSX), may have investments in securities of companies mentioned.
Register for Updates
Renaissance Capital LLC is an SEC-registered investment adviser.
Renaissance Capital Investments, Inc. is a
-registered broker-dealer, and member of
© 2016 Renaissance Capital LLC. All rights reserved.